Transtek(300562)

Search documents
乐心医疗(300562) - 关于变更持续督导保荐代表人的公告
2025-05-16 09:40
关于变更持续督导保荐代表人的公告 乐心医疗 2025 年公告 证券代码:300562 证券简称:乐心医疗 公告编号:2025-043 广东乐心医疗电子股份有限公司 公司董事会对朱宏先生在担任公司保荐代表人期间所做出的贡献表示衷心 的感谢! 特此公告。 广东乐心医疗电子股份有限公司 2025 年 05 月 16 日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司(以下简称"公司")于近日收到保荐机构 国泰海通证券股份有限公司(以下简称"国泰海通")出具的《国泰海通证券股 份有限公司关于更换广东乐心医疗电子股份有限公司持续督导保荐代表人的函》。 国泰海通为公司向特定对象发行股票的保荐机构,指定桑继春女士、朱宏先生为 公司向特定对象发行股票项目持续督导保荐代表人,负责持续督导工作。由于原 保荐代表人朱宏先生因个人原因离职,无法继续从事对公司的持续督导工作。为 保证持续督导工作的有序进行,国泰海通现委派保荐代表人吴超智先生(简历见 附件)接替朱宏先生继续履行持续督导工作。本次保荐代表人更换后,公司向特 定对象发行股票项目持续督导保荐代表人 ...
乐心医疗(300562) - 北京世辉(深圳)律师事务所关于广东乐心医疗电子股份有限公司2025年第一次临时股东大会的法律意见书
2025-05-13 11:20
北京世辉(深圳)律师事务所 关于广东乐心医疗电子股份有限公司 2025 年第一次临时股东大会的 法律意见书 致:广东乐心医疗电子股份有限公司 北京世辉(深圳)律师事务所(以下简称"世辉"或"本所")接受广东乐 心医疗电子股份有限公司(以下简称"公司")的委托,根据《中华人民共和国 证券法》(以下简称"《证券法》")、《中华人民共和国公司法》(以下简称 "《公司法》")、中国证券监督管理委员会《上市公司股东大会规则》(以下 简称"《股东大会规则》")等法律、行政法规、规范性文件和现行有效的《广 东乐心医疗电子股份有限公司章程》(以下简称"《公司章程》")的规定,指 派律师出席了公司于 2025 年 5 月 13 日召开的 2025 年第一次临时股东大会(以 下简称"本次股东大会"),并就本次股东大会的相关事项出具本法律意见书。 为出具本法律意见书,本所律师审查了公司提供的以下文件,包括但不限于: 1.《公司章程》; 2.《第四届董事会第二十三次会议决议公告》; 3.《关于召开 2025 年第一次临时股东大会的通知》; 4.公司本次股东大会股权登记日的股东名册; 5.公司本次股东大会股东到会登记记录及凭证资料; ...
乐心医疗(300562) - 2025年第一次临时股东大会决议公告
2025-05-13 11:20
乐心医疗 2025 年公告 证券代码:300562 证券简称:乐心医疗 公告编号:2025-042 广东乐心医疗电子股份有限公司 特别提示: 1、本次股东大会无否决议案的情形。 1、会议召集人:公司董事会 2025年第一次临时股东大会决议公告 2、会议主持人:董事长潘伟潮先生 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 (一)会议召开情况 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本次股东大会采取现场投票和网络投票相结合的表决方式。 3、会议召开时间: 现场会议时间:2025年05月13日(星期二)下午15:00-16:00 其中:通过深圳证券交易所交易系统进行网络投票的具体时间为2025年05 月13日上午09:15-09:25,09:30-11:30,下午13:00-15:00;通过深圳证券交易所互 联网投票系统投票的具体时间为2025年05月13日09:15至2025年05月13日15:00。 4、会议召开方式: 本次股东大会采取现场投票与网络投票相结合的方式召开: (1)现场投票:股东本人出席现场会议或者通过 ...
乐心医疗收盘下跌2.10%,滚动市盈率44.51倍,总市值31.45亿元
Sou Hu Cai Jing· 2025-05-09 09:57
Group 1 - The core business of the company is health IoT and digital health services, with main products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, fat measuring devices, ECG monitoring equipment, smart bands, and smartwatches [2] - The company has achieved ISO certifications for medical device quality management and has received international certifications such as FDA registration, EU CE certification, and GMP certification from South Korea, indicating its products meet advanced international quality standards [2] - In the latest quarterly report for Q1 2025, the company reported revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, a year-on-year increase of 67.88%, with a gross profit margin of 37.38% [2] Group 2 - As of May 9, the company's stock closed at 14.46 yuan, down 2.10%, with a rolling PE ratio of 44.51 times and a total market capitalization of 3.145 billion yuan [1] - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing the company at the 86th position in the industry ranking [1][3] - On May 9, the company experienced a net outflow of 9.9992 million yuan in main funds, with a total outflow of 32.6116 million yuan over the past five days [1]
乐心医疗收盘上涨3.50%,滚动市盈率43.75倍,总市值30.90亿元
Sou Hu Cai Jing· 2025-04-29 09:52
Group 1 - The core business of the company is health IoT and digital health services, with main products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, fat measuring devices, ECG monitoring equipment, smart bands, and smart watches [2] - The company is recognized as a national high-tech enterprise and has established several research and development centers, focusing on the R&D, production, and sales of home medical health electronic products [2] - The latest financial report indicates that for Q1 2025, the company achieved a revenue of 273 million yuan, representing a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, reflecting a year-on-year growth of 67.88% with a gross profit margin of 37.38% [2] Group 2 - As of April 29, the company's stock closed at 14.21 yuan, up 3.50%, with a rolling PE ratio of 43.75, marking a new low in 18 days, and a total market capitalization of 3.09 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 47.74, with a median of 36.15, placing the company at the 84th position in the industry ranking [1][3] - On April 29, the company experienced a net outflow of 2.93 million yuan in principal funds, although the overall trend over the past five days showed a net inflow of 32.09 million yuan [1]
医药生物行业周报(4月第4周):国产创新药闪耀ASCO
Century Securities· 2025-04-28 02:23
Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].
股市必读:乐心医疗一季报 - 第一季度单季净利润同比增67.88%
Sou Hu Cai Jing· 2025-04-27 18:26
截至2025年4月25日收盘,乐心医疗(300562)报收于13.77元,上涨0.81%,换手率9.48%,成交量15.27万 手,成交额2.11亿元。 当日关注点 交易信息汇总 乐心医疗近日披露了最新的股东户数变动情况。截至2025年3月31日,公司股东户数为2.62万户,较2月 28日减少了13.0户,减幅为0.05%。同时,户均持股数量由上期的8309.0股增加至8313.0股,户均持股市 值为13.04万元。 业绩披露要点 根据乐心医疗2025年一季报,公司主营收入达到2.73亿元,同比上升9.9%;归母净利润为2294.2万元, 同比上升67.88%;扣非净利润为2064.89万元,同比上升73.28%。此外,公司的负债率为34.95%,投资 收益为-70.29万元,财务费用为-244.2万元,毛利率为37.38%。 以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构 成投资建议。 交易信息汇总: 主力资金净流入1944.79万元,而散户资金净流出2124.12万元。 股本股东变化: 截至2025年3月31日,股东户数减少至2.62万户,减 ...
乐心医疗一季度归母净利润同比增长67.88% 携手平安健康深化“医疗+科技”生态布局
Zheng Quan Ri Bao Wang· 2025-04-27 11:43
Group 1 - The core viewpoint of the article highlights the strong financial performance of Guangdong Leshi Medical Electronics Co., Ltd. in Q1 2025, with a revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit attributable to shareholders of 22.94 million yuan, up 67.88% [1] - The company's operating cash flow reached 28.50 million yuan, indicating improved cash generation capabilities [1] - Leshi Medical's strategic partnership with Ping An Health aims to integrate smart hardware, health management services, and insurance payments, enhancing user experience and market penetration [1] Group 2 - The collaboration addresses two major pain points: Leshi Medical's hardware can leverage Ping An Health's extensive insurance user base for market penetration, while Ping An Health can utilize real-time health monitoring data from Leshi Medical to design better insurance products and reduce payout risks [2] - Analysts suggest that this "hardware data collection - service enhancement - insurance value creation" closed-loop model could become a new growth paradigm in the medical technology sector [2]
乐心医疗(300562) - 300562乐心医疗投资者关系管理信息20250427
2025-04-27 11:36
证券代码:300562 证券简称:乐心医疗 广东乐心医疗电子股份有限公司投资者关系活动记录表 编号:2025-006 投资者关系 活动类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 ■其他 2025 年一季报业绩交流 参与单位名 称及人员 天风医药、中邮医药、东吴医药、申万菱信、中信证券、华夏基金、泽 源私募、银河基金、东方港湾、中欧基金、友邦保险、国联民生、长城 财富资管、天治基金、财通资管、人保养老、金科投资、兴银、优益增、 安盛浦银等线上参会的机构。 时间 2025 年 04 月 27 日(星期日)下午 14:30 地点 线上平台 上市公司接 待人员姓名 董事长、总经理:潘伟潮先生 董事、副总经理、财务总监、董事会秘书:黄林香女士 投资者关系 活动主要内 容介绍 公司本次交流通过线上平台进行,主要内容如下: 一、公司介绍及 2025 年一季度经营情况 公司聚焦数字慢病管理领域,依托在智能医疗健康、医疗级可穿戴 等领域产品创新研发、产品品质以及领先的应用技术等方面的独特优 势,将智能健康监测、大数据、AI 人工智能与医疗服务深度融合,持续 ...
乐心医疗接入平安健康生态,开启全天候健康守护新时代
Zheng Quan Shi Bao Wang· 2025-04-25 13:26
在全民健康意识觉醒与慢性病防控需求激增的当下,健康管理正从单一设备监测向全场景、全流程服务跃迁。作为"健康中国"的坚定践行者、数字健康普惠 化的先行者,乐心医疗(300562)(300562.SZ)与平安健康携手共同打造"实时监测-数据互联-即时响应-长程管理"的全场景健康守护解决方案。 以乐心远程心电产品接入平安健康服务体系为例,双方实现"监测异常-精准诊断-保险保障-康复管理"的全周期闭环。 .心脏健康24小时动态守护 用户日常穿戴乐心远程动态心电业务核心产品——智能心电衣,即可实现对心脏健康状况的持续性、长效化监测。监测所获取的心电数据经专业分析后,诊 断结果将同步至平安健康APP。用户通过该平台,不仅能够获取专业心电诊断报告,还可预约平安健康"臻享家医"服务,为用户提供多维度、深层次的报告 解读。 .构建心脏急救生命通道 可穿戴动态心电监测仪 iSENSE-800T 联心电监测衣 类医疗器械 若AI系统检测到用户异常心电信号,互联网医院会审核确认并快速启动响应,危急情况立即通知紧急联系人,构建"预警-诊断-急救"的黄金救援链。 .化解医患风险后顾之忧 在心脏健康监测全流程服务中,医疗责任险会全程护航, ...